Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • CNS Effects
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Terazosin, Urocard, Uroflo, Vicard; Belgium: Hytrin, Terazosabb, Terazosine; Cyprus: Hytrin; Czech Republic: Hytrin, Kornam, Terazosin; Denmark: Sinalfa, Terazosin; Estonia: Terazosin; France: Dysalfa, Hytrine, Terazosine; Germany: Flotrin, Heitrin, Hytrin, Terablock, Teranar, Terazid, Terazoflo, Terazosin, Urozosin; Greece: Hytrin; Hungary: Hytrin, Setegis; Ireland: Hytrin, Terazosin; Italy: Ezosina, Itrin, Prostatil, Terafluss, Teraprost, Terazosina, Unoprost, Urodie, Uroflus; Latvia: Terazosin; Lithuania: Terazosin; Luxembourg: Hytrin; Malta: Hytrin, Terazosin; Netherlands: Hytrin, Terazosine; Poland: Glaprost, Hytrin, Kornam, Setegis, Terazosin; Portugal: Hytrin, Terazosina; Romania: Hytrin, Terazosin; Slovakia: Hytrin, Kornam, Setegis; Slovenia: Kornam; Spain: Alfaprost, Deflox-Amdipharm, Magnurol, Mayul, Sutif, Teraumon, Terazosina, Zayasel; Sweden: Hytrinex, Sinalfa, Terazosin, Terazostad; UK: Hytrin, Terazosin.

North America

Canada: Hytrin, Terazosin; USA: Hytrin, Terazosin.

Latin America

Argentina: Andrin, Benaprost, Blavin, Flumarc, Fosfomik, Geriprost, Isontyn, Panaprost, Proxatan, Rotiaz, Terazosina; Brazil: Hytrin, Terazosina; Mexico: Adecur, Hytrin, Romaken.


Japan: Hytracin, Vasomet.

Drug combinations


Terazosin Hydrochloride: C~19~H~25~N~5~O~4~ HCl 2H~2~O. Mw: 459.92. (1) Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride, dihydrate; (2) 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride dihydrate. CAS-70024-40-7; CAS-63074-08-8 (anhydrous); CAS-63590-64-7 (terazosin)(1980).

Pharmacologic Category

Cardiovascular Drugs; α-Adrenergic Blocking Agents. (ATC-Code: G04CA03).

Mechanism of action

α~1~-Specific blocking agent with minimal α~2~ effects. This allows peripheral postsynaptic blockade, with resultant decrease in arterial tone, while preserving negative feedback loop mediated by peripheral presynaptic α~2~-receptors. Terazosin relaxes smooth muscle of bladder neck, thus reducing bladder outlet obstruction.

Therapeutic use

Management of mild-to-moderate hypertension. Benign prostate hyperplasia.

Pregnancy and lactiation implications

Use with caution in pregnant and nursing women.

Unlabeled use

Pediatric hypertension.


Hypersensitivity to quinazolines (doxazosin, prazosin, terazosin) or any component of the formulation. Concurrent use with PDE-5 inhibitors including sildenafil (>25 mg), tadalafil, or vardenafil.

Warnings and precautions

Discontinue if symptoms of angina occur or worsen. Intraoperative floppy iris syndrome observed in cataract surgery patients on, or previously treated with, α~1~-blockers (causality not established). May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor is introduced. Use with caution in hepatic impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart